Preventing cognitive decline in preclinical Alzheimer's disease
Open accessAbstract
Alzheimer's disease (AD) is a chronic neurodegenerative disease leading to cognitive decline, dementia, and ultimately death. Despite extensive R&D efforts, there are no diseases modifying treatments for AD available. The stage in which patients receive a clinical diagnosis of probable AD may be too late for disease modifying pharmacotherapy. Prevention strategies may be required to successfully tackle AD. Preclinical AD applies to over half of all healthy elderly subjects and manifests by signs of amyloid deposition and/or neuronal injury in the brain, preceding the stage in which symptoms of dementia, cognitive and functional impairment become observable. Prevention trials in preclinical AD require longer and larger clinical trials using biomarkers and cognitive endpoints, which requires collaboration across academia, government and industry.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
The citation lists haven’t been fetched yet
References 37 · Cited by 22
- Authors
- Riedel, W. J.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Riedel, Wim J
- ORCID
- Riedel, Wim J
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 14
- Pages
- 18-22
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2122485874
- Cited by
- 22
- References
- 37
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 4
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Current Opinion in Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease, cognitive decline, prevention, disease-modifying therapy, amyloid deposition, biomarkers, clinical trials, dementia
- MeSH terms
- Aged, Alzheimer Disease, Brain, Clinical Trials as Topic, Cognition Disorders, Cooperative Behavior, Dementia, Humans, Biomarkers, Amyloid beta-Peptides, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
